What one share of Nektar Therapeutics holds
Nektar Therapeutics (Nektar, we) is a clinical stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. Within this growing field, we direct our efforts toward creating new immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses in order to achieve desired therapeutic outcomes.
Nektar Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.25 |
|---|---|
| Profit | −$6.49 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$9.66 |
| Cash and investments | $1.93 |
| Book value | $44.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $11.68 | −$16.65 | $2.66 | $3.79 | — | $16.63 |
| 2010 | $25.15 | −$6.00 | $4.97 | −$13.81 | — | $14.39 |
| 2011 | $9.49 | −$17.79 | $1.29 | −$16.40 | — | $25.92 |
| 2012 | $10.61 | −$22.45 | $1.38 | −$18.33 | — | $6.12 |
| 2013 | $19.30 | −$21.00 | $0.53 | −$5.52 | — | −$11.58 |
| 2014 | $23.73 | −$6.37 | $1.18 | −$17.97 | — | $4.15 |
| 2015 | $26.13 | −$9.19 | $1.27 | −$9.54 | — | $0.71 |
| 2016 | $17.78 | −$16.50 | $0.69 | −$13.26 | — | $8.63 |
| 2017 | $29.60 | −$9.30 | $0.93 | −$8.67 | — | $8.26 |
| 2018 | $99.38 | $56.74 | $1.19 | $58.63 | — | $148.47 |
| 2019 | $9.82 | −$37.77 | $2.25 | −$30.43 | — | $119.43 |
| 2020 | $12.84 | −$37.33 | $0.61 | −$26.92 | — | $89.73 |
| 2021 | $8.34 | −$42.87 | $1.23 | −$35.00 | — | $54.96 |
| 2022 | $7.38 | −$29.51 | $0.46 | −$24.82 | — | $29.17 |
| 2023 | $7.11 | −$21.79 | $0.07 | −$15.27 | — | $10.27 |
| 2024 | $7.18 | −$8.68 | $0.11 | −$12.92 | — | $4.90 |
| 2025 | $3.27 | −$9.73 | $0.01 | −$12.37 | — | $4.41 |
Common questions about Nektar Therapeutics
How much does one share of Nektar Therapeutics earn?
Over the last 12 months, Nektar Therapeutics lost $6.49 for each share on $2.25 of sales.
Does Nektar Therapeutics pay a dividend?
Nektar Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Nektar Therapeutics’s book value per share?
Nektar Therapeutics’s book value is $44.32 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Nektar Therapeutics have?
Each share of Nektar Therapeutics has $1.93 of cash and investments, as of June 30, 2026.
What is Nektar Therapeutics’s free cash flow per share?
−$9.66 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Nektar Therapeutics bought back shares?
Nektar Therapeutics’s share count rose about 174% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.